Literature DB >> 29610934

IL-33 attenuates mortality by promoting IFN-γ production in sepsis.

Qi Bao1, Ran Lv1, Min Lei2.   

Abstract

OBJECTIVE AND
DESIGN: Sepsis remains a major clinical problem with high morbidity and mortality. Interleukin (IL)-33 is a recently described member of the IL-1 family that is widely expressed and functions as a new inflammatory mediator. IL-33 has been reported to protect sepsis, but the underlying mechanisms are not well-elucidated.
MATERIALS AND METHODS: We measured the interferon gamma (IFN-γ) production in septic mice after IL-33 treatment.
RESULTS: IL-33 treatment enhanced the IFN-γ level in blood and promoted mice's survival, so the protective effects of IL-33 depend on IFN-γ. The IL-33 treatment also promoted both γδ T cells and NK cells in septic mice.
CONCLUSION: Our data showed that IL-33 attenuates mortality by promoting IFN-γ production in sepsis.

Entities:  

Keywords:  IFN-γ; IL-33; NK cells; Sepsis; γδ T cells

Mesh:

Substances:

Year:  2018        PMID: 29610934     DOI: 10.1007/s00011-018-1144-9

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  27 in total

1.  Immunomodulatory intervention with Gamma interferon in mice with sepsis.

Authors:  Yu Wang; Bing-Bing Kong; Wen-Ping Yang; Xin Zhao; Rong Zhang
Journal:  Life Sci       Date:  2017-07-12       Impact factor: 5.037

2.  Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection.

Authors:  Jose C Alves-Filho; Fabiane Sônego; Fabricio O Souto; Andressa Freitas; Waldiceu A Verri; Maria Auxiliadora-Martins; Anibal Basile-Filho; Andrew N McKenzie; Damo Xu; Fernando Q Cunha; Foo Y Liew
Journal:  Nat Med       Date:  2010-05-16       Impact factor: 53.440

3.  Isolation of mouse intrahepatic lymphocytes.

Authors:  I N Crispe
Journal:  Curr Protoc Immunol       Date:  2001-05

Review 4.  Sepsis syndromes: understanding the role of innate and acquired immunity.

Authors:  A Oberholzer; C Oberholzer; L L Moldawer
Journal:  Shock       Date:  2001-08       Impact factor: 3.454

Review 5.  The immune system's role in sepsis progression, resolution, and long-term outcome.

Authors:  Matthew J Delano; Peter A Ward
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

Review 6.  Sepsis strategies in development.

Authors:  Steven P LaRosa; Steven M Opal
Journal:  Clin Chest Med       Date:  2008-12       Impact factor: 2.878

7.  Effect of sepsis on tissue adenine nucleotide levels.

Authors:  I H Chaudry; K A Wichterman; A E Baue
Journal:  Surgery       Date:  1979-02       Impact factor: 3.982

8.  The immunoprotective activity of interleukin-33 in mouse model of cecal ligation and puncture-induced sepsis.

Authors:  Shu Li; Feng-Xue Zhu; Xiu-Juan Zhao; You-Zhong An
Journal:  Immunol Lett       Date:  2015-11-18       Impact factor: 3.685

Review 9.  The role of natural killer cells in sepsis.

Authors:  Laurent Chiche; Jean-Marie Forel; Guillemette Thomas; Catherine Farnarier; Fréderic Vely; Mathieu Bléry; Laurent Papazian; Eric Vivier
Journal:  J Biomed Biotechnol       Date:  2011-05-14

10.  Interferon gamma production by natural killer (NK) cells and NK1.1+ T cells upon NKR-P1 cross-linking.

Authors:  H Arase; N Arase; T Saito
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

View more
  3 in total

Review 1.  IL-33 in obesity: where do we go from here?

Authors:  Marcos Felipe Andrade de Oliveira; André Talvani; Etel Rocha-Vieira
Journal:  Inflamm Res       Date:  2019-01-17       Impact factor: 4.575

2.  Interleukin (IL)-33 immunobiology in asthma and airway inflammatory diseases.

Authors:  Rohit Gaurav; Jill A Poole
Journal:  J Asthma       Date:  2021-12-27

3.  Interleukin-33 improves local immunity during Gram-negative pneumonia by a combined effect on neutrophils and inflammatory monocytes.

Authors:  Ivan Ramirez-Moral; Dana C Blok; Jochem H Bernink; M Isabel Garcia-Laorden; Sandrine Florquin; Louis Boon; Cornelis Van't Veer; Matthias Mack; Simona Saluzzo; Sylvia Knapp; Hergen Spits; Alex F de Vos; Tom van der Poll
Journal:  J Pathol       Date:  2021-01-19       Impact factor: 7.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.